JPX and lung cancer: In this work, we discovered a novel ceRNET driven by JPX and involving miR-378a-3p and its different mRNAs targets, eliciting shared oncogenic pathways, thus consistently and ultimately refining the oncogenic role of JPX in lung cancer, particularly in LUAD, the most common subtype of NSCLC.